Jared Kelly - 11 Feb 2026 Form 4 Insider Report for ONCOLYTICS BIOTECH INC (ONCY)

Role: Chief Executive Officer, Director
Signature: /s/ Kirk Look, Attorney-in-Fact
Issuer symbol: ONCY
Transactions as of: 11 Feb 2026
Net transactions value: +$29,521
Form type: 4
Filing time: 13 Feb 2026, 07:00:32 UTC
Previous filing: 02 Jan 2026
Next filing: 13 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kelly Jared	Chief Executive Officer, Director	C/O ONCOLYTICS BIOTECH INC., 4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO	/s/ Kirk Look, Attorney-in-Fact	13 Feb 2026	0002103581

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ONCY	Common Shares	Purchase	$4,682	+5,600	+7.6%	$0.8360	79,500	11 Feb 2026	Direct	F1
transaction	ONCY	Common Shares	Purchase	$24,839	+29,500	+37%	$0.8420	109,000	12 Feb 2026	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.820 to $0.856, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.820 to $0.856, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.